Development Center for Biotechnology

National Health Research Institutes

Dcb-usa LLC

Asustek Computer Inc.

Academia Sinica

Miics & Partners (shenzhen) Co., Ltd.

Chao-Yang Huang

Jiann-Shiun Lai

Shih-Chong Tsai

Ying-Yung Lok

Ko-Jiunn Liu

Neng-Yao Shih

Ta-Tung Yuan

Li-Tzong Chen

Shih-Chi Tseng

Cheng-Chou Yu

Chia-Cheng Wu

Wei-Ting Sun

Chung-Hsiun Wu

Ya-Wei Tsai

Chung-Yi Wu

Shih-Hsien Chuang

Wei-Long Lee

Chiung-Tong Chen

Pen-Uei Lu

Yuan-Tsong Chen

Chih-Yung Hu

Szu-Liang Lai

Wei-Chih Hsu

Win-Yin Wei

Young-Sun Lin

Woan-Eng Chan

Jin-Yu Ko

Shu-Ping Yeh

Wun-Huei Lin

Chun-Liang Lai

Jia-ni Tian

Tzung-Jie Yang

Mei-Ling Hou

Tzu-chin Wu

Shih-Liang Hsiao

Ying-Shuan Lailee

Liang-Yu Hsia

Te-Kai Tseng

Andrew Yueh

Han-Shu Hu

Ren-Huang Wu

Pei-Shan Wu

Chi-Kuan Chen

Hung-Ling Wang

Da-Yu Wu

Jia-Wei Chou

Tai-Yin Lin

Tzu-Yu Kung

Mei-Chieh Ku

Hsien-Yu Tsai

Po-Yin Lin

Jiann-shiun Lai

Yu-Ying Lin

A humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. Also, a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR1 in a sample.

Humanized anti-human neurotensin receptor 1 antibodies and their uses

The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof

An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

Antibodies specific to alpha-enolase and uses thereof

An electronic device is provided. The electronic device comprises: a storage for storing interaction setting information and behavior setting information; an interaction interface; and a processor electrically connected to the storage and the interaction interface. When the processor receives a behavior-driving command from the interaction interface, the processor is configured to select the behavior setting information and the interaction setting information according to the behavior-driving command. The processor is configured to perform a behavior according to the behavior setting information. The processor is further configured to perform an interaction operation based on the behavior according to the behavior setting information and the interaction setting information when the behavior is had. A control method and a non-transitory computer readable storage medium are also provided.

Control method, electronic device and non-transitory computer readable storage medium

A charging pile includes a case and a charging gun base. The charging gun base is received in the case. The charging gun base is exposed from a side of the case. The charging gun base further includes a cover and a snap unit. The cover is coupled onto the case through the snap unit. The cover is rotatable relative to the case, thereby covering or exposing the charging gun base. When covering, the cover renders the charging gun base waterproof.

Charging pile

A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy

An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

Anti-granulysin antibodies and methods of use thereof

The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection.

Anti-human cytomegalovirus antibodies

Growing community of inventors

Taipei, Taiwan

Chao-Yang Huang